Characteristics of DLBCL patients receiving rituximab originator or rituximab biosimilars as part of R-CHOP treatment regimen
| . | Rituximab originator . | Rituximab biosimilars . | . | ||
|---|---|---|---|---|---|
| Characteristic . | (N = 3553) . | (N = 876) . | P value . | ||
| Female, no. (%) | 1466 | (41.3) | 344 | (39.3) | .283 |
| Age, y, median (range) | 68 | (18-95) | 68 | (21-95) | .054 |
| Age, y, no. (%) | |||||
| ≤60 | 1092 | (30.7) | 232 | (26.5) | .014 |
| Ann Arbor stage (%) | |||||
| I-II | 1282 | (36.1) | 305 | (34.8) | .333 |
| III-IV | 2257 | (63.5) | 570 | (65.1) | |
| Unknown | 14 | (0.4) | 1 | (0.1) | |
| Lactate dehydrogenase, no. (%) | |||||
| Normal | 1668 | (46.9) | 374 | (42.7) | .066 |
| Elevated | 1819 | (51.2) | 487 | (55.6) | |
| Unknown | 66 | (1.9) | 15 | (1.7) | |
| WHO performance status, no. (%) | |||||
| 0-2 | 1880 | (52.9) | 503 | (57.4) | .044 |
| 3-4 | 75 | (2.1) | 20 | (2.3) | |
| Unknown | 1598 | (45.0) | 353 | (40.3) | |
| Number of extranodal sites, no. (%) | |||||
| 0–1 | 2550 | (71.8) | 653 | (74.5) | .210 |
| >1 | 1001 | (28.2) | 223 | (25.5) | |
| Unknown | 2 | (0.06) | 0 | (0) | |
| IPI score, no. (%) | |||||
| Low (0-1) | 682 | (1929) | 150 | (17.1) | .133 |
| Low-intermediate (2) | 464 | (13.1) | 129 | (14.7) | |
| High-intermediate (3) | 463 | (13.0) | 129 | (14.7) | |
| High (4-5) | 546 | (15.4) | 148 | (16.9) | |
| Unknown | 1398 | (39.4) | 320 | (36.5) | |
| Time until treatment, days, median | 24 | (15-36) | 24 | (14-38) | .314 |
| Number of cycles, no. (%) | |||||
| <6 | 922 | (25.9) | 241 | (27.5) | .004 |
| 6 | 1566 | (44.1) | 426 | (48.6) | |
| >6 | 1062 | (29.9) | 209 | (23.9) | |
| Unknown | 3 | (0.1) | 0 | (0) | |
| . | Rituximab originator . | Rituximab biosimilars . | . | ||
|---|---|---|---|---|---|
| Characteristic . | (N = 3553) . | (N = 876) . | P value . | ||
| Female, no. (%) | 1466 | (41.3) | 344 | (39.3) | .283 |
| Age, y, median (range) | 68 | (18-95) | 68 | (21-95) | .054 |
| Age, y, no. (%) | |||||
| ≤60 | 1092 | (30.7) | 232 | (26.5) | .014 |
| Ann Arbor stage (%) | |||||
| I-II | 1282 | (36.1) | 305 | (34.8) | .333 |
| III-IV | 2257 | (63.5) | 570 | (65.1) | |
| Unknown | 14 | (0.4) | 1 | (0.1) | |
| Lactate dehydrogenase, no. (%) | |||||
| Normal | 1668 | (46.9) | 374 | (42.7) | .066 |
| Elevated | 1819 | (51.2) | 487 | (55.6) | |
| Unknown | 66 | (1.9) | 15 | (1.7) | |
| WHO performance status, no. (%) | |||||
| 0-2 | 1880 | (52.9) | 503 | (57.4) | .044 |
| 3-4 | 75 | (2.1) | 20 | (2.3) | |
| Unknown | 1598 | (45.0) | 353 | (40.3) | |
| Number of extranodal sites, no. (%) | |||||
| 0–1 | 2550 | (71.8) | 653 | (74.5) | .210 |
| >1 | 1001 | (28.2) | 223 | (25.5) | |
| Unknown | 2 | (0.06) | 0 | (0) | |
| IPI score, no. (%) | |||||
| Low (0-1) | 682 | (1929) | 150 | (17.1) | .133 |
| Low-intermediate (2) | 464 | (13.1) | 129 | (14.7) | |
| High-intermediate (3) | 463 | (13.0) | 129 | (14.7) | |
| High (4-5) | 546 | (15.4) | 148 | (16.9) | |
| Unknown | 1398 | (39.4) | 320 | (36.5) | |
| Time until treatment, days, median | 24 | (15-36) | 24 | (14-38) | .314 |
| Number of cycles, no. (%) | |||||
| <6 | 922 | (25.9) | 241 | (27.5) | .004 |
| 6 | 1566 | (44.1) | 426 | (48.6) | |
| >6 | 1062 | (29.9) | 209 | (23.9) | |
| Unknown | 3 | (0.1) | 0 | (0) | |
Statistically significant P values (P < .05) are presented in bold.